Mosaic Q3: Cost Discipline Meets Sulfur and Phosphate Constraints

Transcript intelligence

What changed

Compared with Q2, management’s tone shifted from cautious to confident, with the current call emphasizing a four-year sulfur contract at $615 per ton for Q4, record Esterhazy potash production, and a 2026 Biosciences revenue outlook of $135 million. The prior call had highlighted a $1.2 billion capex plan and expected working-capital release; the current analysis instead describes capex targeted below $1 billion and SG&A expected below $500 million in 2027. These are management’s statements and plans, not confirmed outcomes.

Guidance delta

Overall guidance sentiment was maintained. Management’s current outlook includes capex below $1 billion, 2027 SG&A below $500 million, and positive Biosciences ambitions; phosphate curtailments remain tied to affordable sulfur availability. The supplied analysis does not indicate a broad guidance reset.

Key takeaways

• Management says phosphate curtailments are aligned with affordable sulfur availability, preserving cash and inventory.
• Potash was described as a strong cash generator, with record production at Esterhazy.
• Biosciences sales doubled year over year; management cited $135 million of expected 2026 revenue and a $200 million EBITDA target by 2030.
• Management described a stronger balance sheet following debt refinancing and asset divestitures.

Management priorities

• Secure favorable sulfur supply and manage phosphate production accordingly.
• Keep capex below $1 billion and SG&A below $500 million in 2027.
• Expand Biosciences, including 8–10 product launches in 2026.
• Advance the Araxa sale and Canadian land divestitures while prioritizing high-return projects.